Signposts to the Promised Land in Alopecia Areata

    September 2022 in “ Journal of Investigative Dermatology ”
    Dmitri Wall, Huw Rees, Laita Bokhari, Nekma Meah, Katherine York, Rodney Sinclair
    New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This study found that the Severity of Alopecia Tool score does not predict the quality of life in patients with alopecia areata, suggesting patient-reported outcomes better reflect the impact on life quality. Our plain-language summary of this paper — not a Tressless recommendation.
    Alopecia areata (AA) is an autoimmune disease affecting hair and nails, impacting 329,500-659,000 people in the United States. The Severity of Alopecia Tool (SALT) score, traditionally used to measure disease severity, does not accurately predict the quality of life (QoL) impact, as it overlooks eyebrow and eyelash loss. This study suggests that patient-reported outcomes provide a more accurate depiction of diminished life quality. It also emphasizes the need to redefine disease severity considering emerging therapies and their costs. The study advocates for a shift in clinical practice towards patient perception of disease activity or the Patient Global Impression of Severity scale.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results